Hepatocellular Carcinomas in Cirrhotic and Noncirrhotic Human Livers Share Angiogenic Characteristics

BACKGROUND: The antiangiogenic drug sorafenib has been shown to be an effective treatment for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. It might also be effective in noncirrhotic HCC provided that the angiogenic properties of both tumor types are comparable. The aim of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Wenjiao, Gouw, Annette S. H., van den Heuvel, Marius C., Molema, Grietje, Poppema, Sibrand, van der Jagt, Eric J., de Jong, Koert P.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Hepatobiliary Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868164/
https://www.ncbi.nlm.nih.gov/pubmed/20087783
http://dx.doi.org/10.1245/s10434-009-0900-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868164/
https://www.ncbi.nlm.nih.gov/pubmed/20087783
http://dx.doi.org/10.1245/s10434-009-0900-z

Ejemplares similares